+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019

  • ID: 4894230
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1463 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • CARsgen Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Jazz Pharmaceuticals Plc
  • Nohla Therapeutics Inc
  • Sanofi
  • MORE
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 75, 77, 6, 5, 87, 13 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 29, 22, 27, 2 and 1 molecules, respectively.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • CARsgen Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Jazz Pharmaceuticals Plc
  • Nohla Therapeutics Inc
  • Sanofi
  • MORE
Introduction
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..6), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019

List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Adlai Nortye Biopharma Co Ltd
  • Aeglea BioTherapeutics Inc
  • Aileron Therapeutics Inc
  • Aleta Biotherapeutics Inc
  • Altor Bioscience LLC
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • Anhui Anke Biotechnology (Group) Co Ltd
  • Apexian Pharmaceuticals Inc
  • Applied Therapeutics Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • AUM Biosciences Pte Ltd
  • Autolus Therapeutics Plc
  • Avalon GloboCare Corp
  • Ayala Pharmaceuticals Inc
  • Beam Therapeutics Inc
  • Beijing Immunochina Medical Science & Technology Co Ltd
  • Bellicum Pharmaceuticals Inc
  • Bio-Cancer Treatment International Ltd
  • Bio-Path Holdings Inc
  • Bioceltech Therapeutics Ltd
  • Biocure Technology Inc
  • BioSight Ltd
  • Bristol-Myers Squibb Co
  • CanBas Co Ltd
  • CARsgen Therapeutics Ltd
  • CASI Pharmaceuticals Inc
  • Cell Medica Ltd
  • Cellectis SA
  • Cellestia Biotech AG
  • Cellipse SAS
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • Chesapeake Therapeutics LLC
  • China Immunotech Co Ltd
  • CRISPR Therapeutics AG
  • Cyclacel Pharmaceuticals Inc
  • Cyteir Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals Inc
  • Delta-Fly Pharma Inc
  • DevaCell Inc
  • Dialectic Therapeutics Inc
  • Diazon Pharmaceuticals Inc
  • DiNonA Inc
  • Elf Zone Inc
  • Eli Lilly and Co
  • Enzyme by Design Inc
  • Epizyme Inc
  • Erytech Pharma SA
  • Eureka Therapeutics Inc
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Felicitex Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Fusion Pharma LLC
  • Gamida Cell Ltd
  • GEMoaB Monoclonals GmbH
  • Generon (Shanghai) Corp Ltd
  • Genexine Inc
  • Gilead Sciences Inc
  • Gmax Biopharm Ltd
  • Gracell Bio
  • GT Biopharma Inc
  • Hangzhou Minsheng Pharmaceutical Group Co Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • HemoGenyx LLC
  • HighPass Bio Inc
  • Housey Pharmaceutical Research Laboratories LLC
  • HRAIN Biotechnology Co Ltd
  • Hummingbird Bioscience Pte Ltd
  • iCell Gene Therapeutics LLC
  • iDD biotech SAS
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunotech Biopharm Ltd
  • Inatherys
  • Incuron LLC
  • Incysus Therapeutics Inc
  • Incyte Corp
  • Innovative Cellular Therapeutics Co Ltd
  • Interprotein Corp
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Juventas Cell Therapy Ltd
  • Karyopharm Therapeutics Inc
  • Kecellitics Biotech Co Ltd
  • Kronos Bio Inc
  • LegoChem Biosciences Inc
  • Les Laboratoires Servier SAS
  • Lin Bioscience Inc
  • MAA Laboratories Inc
  • MacroGenics Inc
  • Magenta Therapeutics Inc
  • MannKind Corp
  • Marker Therapeutics Inc
  • Medivir AB
  • Merck & Co Inc
  • Meryx Inc
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • Molecular Templates Inc
  • Nanjing Bioheng Biotech Co Ltd
  • Nanjing Iaso Biotherapeutics Co Ltd
  • Nanjing KAEDI Biotech Inc
  • Nanjing Legend Biotech Co Ltd
  • Nanovalent Pharmaceuticals Inc
  • NantKwest Inc
  • Nimbus Therapeutics LLC
  • Nkarta Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • NovImmune SA
  • NovoMedix LLC
  • Omeros Corp
  • Oncoceutics Inc
  • Onconova Therapeutics Inc
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Orca Biosystems Inc
  • OSE Immunotherapeutics
  • Pascal Biosciences Inc
  • PeproMene Bio Inc
  • PersonGen Biomedicine Suzhou Co Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Polyphor AG
  • Precision Biosciences Inc
  • Protheragen Inc
  • PTC Therapeutics Inc
  • Regenacy Pharmaceuticals LLC
  • Regeneron Pharmaceuticals Inc
  • Retrotherapy LLC
  • Samus Therapeutics LLC
  • Sanofi
  • Sareum Holdings Plc
  • SciTech Development LLC
  • SELLAS Life Sciences Group Inc
  • Selvita SA
  • Senz Oncology Pty Ltd
  • Shanghai GeneChem Co Ltd
  • Shanghai Longyao Biotechnology Inc Ltd
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shenzhen BinDeBio Ltd
  • Sian Wuhan Medical Technology Co Ltd
  • SpecificiT Pharma Inc
  • Spectrum Pharmaceuticals Inc
  • Spherix Inc
  • Sun Pharma Advanced Research Company Ltd
  • SunRock Biopharma SL
  • Syndax Pharmaceuticals Inc
  • SYNIMMUNE GmbH
  • Takara Bio Inc
  • Takeda Pharmaceutical Co Ltd
  • TC BioPharm Ltd
  • TCR2 Therapeutics Inc
  • TheraPharm Deutschland GmbH
  • Tianjin Mycure Medical Technology Co Ltd
  • Tolero Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • Triphase Accelerator Corp
  • UWELL Biopharma Inc
  • Vor BioPharma Inc
  • Wugen Inc
  • Wuhan Bio-Raid Biotechnology Co Ltd
  • Xbrane Biopharma AB
  • Xencor Inc
  • Zhejiang Teruisi Pharmaceutical Inc
  • Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
  • ZIOPHARM Oncology Inc
  • Zovis Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll